Tumor-associated antigen-specific T cell receptor complex (TAA-specific TCR complex)

The tumor-associated antigen-specific T cell receptor (TCR) complex is a multi-subunit transmembrane assembly responsible for recognizing intracellular proteins processed into peptides and presented by human leukocyte antigens (HLA) on the surface of tumor cells [NCBI]. Unlike chimeric antigen receptors (CARs) which recognize surface proteins, the TCR complex can target a broader range of antigens derived from internal cellular compartments [PubMed: 30123819]. This complex typically consists of an antigen-binding heterodimer (alpha and beta chains) non-covalently associated with CD3 signaling subunits [UniProt]. In therapeutic contexts, T cells are often engineered to express a high-affinity TCR specific to a particular tumor-associated antigen, such as MAGE-A4 or NY-ESO-1 [Nature Medicine]. Upon engagement with the cognate peptide-HLA complex, the TCR triggers a signaling cascade that results in the directed lysis of the malignant cell and the secretion of pro-inflammatory cytokines [Journal of Clinical Oncology]. This approach is particularly promising for solid tumors where surface targets are limited, though it requires specific HLA matching for patient eligibility [FDA]. Notable examples of therapies targeting this complex include afamitresgene autoleucel, which was recently approved for the treatment of advanced synovial sarcoma [FDA].

Other names

T-cell receptor complexEngineered T-cell receptorTAA-TCRAntigen-specific TCR

The complex recognizes specific tumor-associated antigen (TAA) peptides presented by Major Histocompatibility Complex (MHC) molecules on the surface of cancer cells. Upon binding, the TCR complex undergoes conformational changes that trigger intracellular signaling through the CD3 subunits, leading to T-cell activation, proliferation, and the release of cytotoxic granules (perforin and granzymes) and cytokines to eliminate the target tumor cell.